@article {Wu2020.05.22.20110635, author = {Qian Wu and Evgenia Kvitko and Amber Jessop and Shannon Williams and Ryan C. Costantino and Kaury Kucera and David Light}, title = {Analysis of Crowdsourced Metformin Tablets from Individuals Reveals Widespread Contamination with N-Nitrosodimethylamine (NDMA) in the United States}, elocation-id = {2020.05.22.20110635}, year = {2020}, doi = {10.1101/2020.05.22.20110635}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Recent reports of metformin drug products contaminated with unacceptable levels of the probable human carcinogen N-Nitrosodimethylamine (NDMA) prompted a national sampling of post-market metformin drug products. To most broadly sample the market and minimize supply chain bias, metformin medication samples were crowdsourced directly from individuals across many states in the United States. 128 samples were received, and liquid chromatography-high resolution mass spectrometry tests for a panel of nitrosamines revealed significant levels of NDMA that trend with labeling company. 42\% of all medication samples contained detectable levels of NDMA and, when scaled to maximum daily tablet dose, 36\% of all medication samples contained NDMA levels exceeding the FDA daily acceptable intake limit. The highest NDMA detection from the tested samples was 1565 ng per tablet, which, when commonly taken four times a day, is 65 times the United States Food and Drug Administration (FDA) acceptable daily intake limit. Results underscore the need for immediate product recalls of tainted medications and an overall investigation of metformin manufacturing practices.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding sources or grants were used in support of this research study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGranular data is available in the supplemental table and further requests may be made to the corresponding author.}, URL = {https://www.medrxiv.org/content/early/2020/06/01/2020.05.22.20110635}, eprint = {https://www.medrxiv.org/content/early/2020/06/01/2020.05.22.20110635.full.pdf}, journal = {medRxiv} }